# US 2025/0018066 A1 · Ophthalmic dye composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0018066 A1
- Document ID: US20250018066A1
- Status: Published application
- Kind: A1
- Application number: 18/772,309
- Filed: 2024-07-15
- Published: 2025-01-16
- Earliest claimed: 2016-04-22
- Assignees: Vitreq B.V.
- Applicants: Vitreq B.V.
- Inventors: Detlef Gabel; Andreas Matthias Mohr; Frank Ruseler
- Web page: https://patentgrep.com/patent/US20250018066A1

## CPC

- A61K 49/006: {Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery}
- A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)}
- A61F 9/007: Methods or devices for eye surgery
- A61K 49/0023: {Di-or triarylmethane dye (xanthene dyes A61K49/0041)}
- A61K 49/003: {Thiazine dyes}
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of medicine, specifically to ophthalmic surgery, more specifically to an improved staining composition for ophthalmic surgery with low toxicity and increased staining efficiency.

## Claims

### Claim 1

A method of ophthalmic surgery, comprising administration of a composition to a subject, said composition comprising a dye and further comprising diglycerol or triglycerol as an agent to increase the density and viscosity of the composition, wherein the total concentration of the diglycerol or triglycerol in the composition is within the range of 0.1% to 25% (v/v), wherein the composition is sterilized and is for staining an ophthalmic structure during surgery, and wherein the diglycerol or triglycerol increases the staining contrast of the dye

### Claim 2 (depends on 1)

The method according to claim 1, wherein the dye in the composition is selected from the group consisting of Trypan Blue, Janus Green, Methyl Green, Methylene Blue, Crystal Violet, Methyl Violet, Ethyl Violet, Evans Blue, Methyl Blue and their respective pharmaceutically acceptable salts and hydrates thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the total concentration of the diglycerol and triglycerol in the composition is within the range of 2% to 20% (v/v).

### Claim 4 (depends on 3)

The method according to claim 3, wherein the total concentration of the diglycerol and triglycerol in the composition is within the range of 3% to 6% (v/v).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition further comprises a Gadolinium complex to enhance the density and to enhance staining of the ophthalmic structure.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the concentration of the Gadolinium complex in the composition is within the range of 0.01 M to 0.1 M.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition comprises Trypan Blue or a pharmaceutically acceptable salt or hydrate thereof and further comprises a dye selected from the group consisting of Methyl Blue, Methylene Blue, Janus Green, Methyl Green, Crystal Violet, Methyl Violet, Ethyl Violet, Evans Blue and their respective pharmaceutically acceptable salts and hydrates thereof.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the composition comprises Trypan Blue and Methyl Blue, Trypan Blue and Methylene Blue or Trypan Blue and Janus Green.

### Claim 9 (depends on 1)

The method according to claim 1, wherein in the composition:
Methyl Blue, if present, has a concentration within the range of 0.001% (w/v) to 0.4% (w/v),
Methylene Blue, if present, has a concentration within the range of 0.001% (w/v) to 0.1% (w/v),
Janus Green, if present, has a concentration within the range of 0.001% (w/v) to 0.1% (w/v),
Methyl Green, if present, has a concentration within the range of 0.001% (w/v) to 0.1% (w/v),
Crystal Violet, if present, has a concentration within the range of 0.001% (w/v) to 0.1% (w/v),
Methyl Violet, if present, has a concentration within the range of 0.001% (w/v) to 0.1% (w/v),
Ethyl Violet, if present, has a concentration within the range of 0.001% (w/v) to 0.1% (w/v),
Evans Blue, if present, has a concentration within the range of 0.001% (w/v) to 0.4% (w/v),
Indocyanine Green, if present, has a concentration within the range of about 0.001% (w/v) to about 0.4% (w/v), and,
Trypan Blue, if present, has a concentration within the range of 0.001% (w/v) to 0.25% (w/v.

### Claim 10 (depends on 9)

The method according to claim 9, wherein in the composition:
Methyl Blue, if present, has a concentration within the range of 0.01% (w/v)) to 0.1%,
Methylene Blue, if present, has a concentration within the range of 0.01% (w/v) to 0.1% (w/v),
Janus Green, if present, has a concentration within the range of 0.005% (w/v) to 0.01% (w/v),
Methyl Green, if present, has a concentration within the range of 0.01% (w/v) to 0.05% (w/v),
Crystal Violet, if present, has a concentration within the range of 0.01% (w/v) to 0.05% (w/v),
Methyl Violet, if present, has a concentration within the range of 0.01% (w/v) to 0.05% (w/v),
Ethyl Violet, if present, has a concentration within the range of 0.01% (w/v) to 0.05% (w/v),
Evans Blue, if present, has a concentration within the range of 0.025% (w/v) to 0.1% (w/v),
Indocyanine Green, if present, has a concentration within the range of 0.025% (w/v) to 0.1% (w/v), and,
Trypan Blue, if present, has a concentration within the range of 0.01% (w/v) to 0.25% (w/v).

### Claim 11 (depends on 1)

The method according to claim 1, wherein the ophthalmic structure is the internal limiting membrane (ILM) the epiretinal membrane (ERM) or the anterior cavity.
